Abstract: An optical probe imaging system includes an optical probe with a multicore optical fiber positioned therein. Distal optics are optically coupled to the distal end of the multicore fiber that image light propagating in the multicore fiber so as to generate a light pattern on a sample that is based on a relative position of at least two cores at a distal facet of the multicore fiber. A distal motor is mechanically coupled to the optical probe so that a motion of the distal motor causes the light pattern to traverse a path across the sample. An optical receiver is coupled to the proximal end of the multicore fiber and receives light that has traversed the path across the sample and then generates an electrical signal corresponding to the received light. A processor maps the electrical signal to a representation of information about the sample, wherein the mapping is based on the relative position of at least two cores at the distal facet of the multicore fiber and on the motion of the distal motor.

Abstract: Medical devices, systems, and methods for treating conditions using antithrombin-heparin conjugates are disclosed. For example, medical devices can be coated with antithrombin-heparin (ATH) resulting in reduced thrombogenicity. Various conditions can likewise be treated with ATH.

Abstract: An optical probe imaging system includes an optical probe having a multicore optical fiber. Distal optics image light propagating in the multicore optical fiber so as to generate a light pattern on a sample that is based on a relative position of the cores. A distal motor causes the light pattern to traverse a path across the sample. An optical receiver includes a first receiver receiving light that has traversed the path across the sample from one of the at least two cores and a second receiver receiving light that has traversed the path across the sample from the other of the cores, such that the first receiver and the second receiver detect light in parallel. A processor maps relative position of the cores at the distal facet based on signals generated by the receiver.

Abstract: An optical probe imaging system includes an optical probe with a multicore optical fiber positioned therein. Distal optics are optically coupled to the distal end of the multicore fiber that image light propagating in the multicore fiber so as to generate a light pattern on a sample that is based on a relative position of at least two cores at a distal facet of the multicore fiber. A distal motor is mechanically coupled to the optical probe so that a motion of the distal motor causes the light pattern to traverse a path across the sample. An optical receiver is coupled to the proximal end of the multicore fiber and receives light that has traversed the path across the sample and then generates an electrical signal corresponding to the received light. A processor maps the electrical signal to a representation of information about the sample, wherein the mapping is based on the relative position of at least two cores at the distal facet of the multicore fiber and on the motion of the distal motor.

Abstract: A system for regulating reactive power flow of one or more inverters coupled to an electrical grid. The system includes one or more voltage regulators coupled between a voltage output of a feeder of the electrical grid and one or more inverters configured to generate or consume reactive power as a function of observed voltage. The one or more voltage regulators is configured to provide one or more output control voltages to control reactive power flow of the one or more inverters.

Abstract: Compositions and methods for preventing thrombogenesis can include antithrombin and heparin. In one example, a conjugate of antithrombin and heparin where at least 50 wt % of the heparin is conjugated to antithrombin can be present. Furthermore, in one example, at least 98 wt % of the heparin in the composition has a molecular weight greater than 3,000 Daltons.

Abstract: Medical devices, systems, and methods for treating conditions using antithrombin-heparin conjugates are disclosed. For example, medical devices can be coated with antithrombin-heparin (ATH) resulting in reduced thrombogenicity. Various conditions can likewise be treated with ATH.

Abstract: Compositions and methods for preventing thrombogenesis can include antithrombin and heparin. In one example, a conjugate of antithrombin and heparin where at least 50 wt % of the heparin is conjugated to antithrombin can be present. Furthermore, in one example, at least 98 wt % of the heparin in the composition has a molecular weight greater than 3,000 Daltons.

Abstract: A system for cancelling fundamental neutral current on a multi-phase power distribution grid. The system includes a controller coupled to the power distribution grid responsive to a neutral current signal configured to determine a first corrective current based on at least the neutral current signal. A power module responsive to the controller is configured to generate the first corrective current. A transformer subsystem includes primary windings coupled to the power distribution grid and a zero sequence voltage point coupled to the power module. The transformer subsystem is configured to transform the first corrective current into a second corrective current coupled to the power distribution grid such that the second corrective current cancels all or part of a fundamental neutral current. The power module is configured as a four-quadrant power module which provides real power flow in either direction between the power module and the transformer subsystem at the zero sequence voltage point.

Abstract: A system for regulating reactive power flow of one or more inverters coupled to an electrical grid. The system includes one or more voltage regulators coupled between a voltage output of a feeder of the electrical grid and one or more inverters configured to generate or consume reactive power as a function of observed voltage. The one or more voltage regulators is configured to provide one or more output control voltages to control reactive power flow of the one or more inverters.

Abstract: Novel conjugates of glycosaminoglycans, particularly heparin and dermatan sulfate, and amine containing species and therapeutic uses thereof are described. In particular, mild methods of conjugating heparins to proteins, such as antithrombin III and heparin cofactor II, which provide covalent conjugates which retain maximal biological activity are described. Uses of these conjugates to prevent thrombogenesis, in particular in lung airways, such as found in infant and adult respiratory distress syndrome, and on surfaces in contact with blood are also described.

Abstract: A shared protect link extends between adjacent nodes that are shared by two or more adjacent BLSR rings. The shared protect link obviates the need for separate protect links between the adjacent nodes for each of the rings. A composite BLSR controller resides in each of the adjacent nodes. The composite BLSR controllers coordinate usage of the shared protect link, for example as a result of a span switch or a ring switch request. The composite BLSR controllers also coordinate transmission of signaling information for each of the rings over the common span between the adjacent nodes. In one embodiment, the signaling information is sent over separate channels of the common span. In another embodiment, the signaling information is multiplexed over the shared protect link. Each ring can be assigned a ring ID. The communication protocol between the adjacent nodes can be modified to tag the signaling information with the appropriate ring ID.

Abstract: Each span of a communication network, such as a BLSR ring, is assigned a unique span ID. When a node of the network detects a failure in a span (including a straddling span) of the network, the node exchanges commands, according to an automatic protection switching (APS) protocol, that request other nodes of the network to switch network traffic from a working span (including a straddling span) to a protect span. The commands specify the working span by its span ID, without necessarily specifying a source node ID or a destination node ID for the commands. The span ID occupies fewer bits in the commands than a combination of the source node ID and the destination node ID. Consequently, the messages can accommodate span IDs larger than four bits, and networks can have more than 16 nodes. Alternatively, the commands specify a destination node ID without a span ID or a source node ID, or the commands specify a source node ID without a span ID or a destination node ID.

Abstract: Novel conjugates of glycosaminoglycans, particularly heparin and dermatan sulfate, and amine containing species and therapeutic uses thereof are described. In particular, mild methods of conjugating heparins to proteins, such as antithrombin III and heparin cofactor II, which provide covalent conjugates which retain maximal biological activity are described. Uses of these conjugates to prevent thrombogenesis, in particular in lung airways, such as found in infant and adult respiratory distress syndrome, and on surfaces in contact with blood are also described.